PDSBPDS Biotechnology
About PDS Biotechnology
PDS Biotechnology (NASDAQ:PDSB) specializes in the development of immunotherapies to fight various types of cancer and infectious diseases. Central to its operations is the Versamune® platform, a proprietary technology designed to activate the body's immune response towards specific diseases. PDS Biotechnology is currently focused on advancing its pipeline, including lead candidates for treating HPV-associated cancers and a collaboration for a COVID-19 vaccine. The company's objective is to deliver innovative treatments that improve patient outcomes and address unmet medical needs by harnessing the power of the immune system.
What is PDSB known for?
Snapshot
Public US
Ownership
2005
Year founded
27
Employees
New Jersey, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of PDS Biotechnology
- Versamune® technology, a platform aimed at advancing immune-activating therapies for cancer.
- PDS0101, a therapeutic vaccine targeting HPV-related cancers.
- Combination therapies leveraging PDS0101 for more effective cancer treatment options.
- Development of vaccines for infectious diseases utilizing Versamune® and other proprietary technologies.
- Research into novel immunotherapies aiming to treat a broader range of cancers.
- Collaboration with pharmaceutical companies to enhance and co-develop the existing pipeline of cancer immunotherapies.
PDS Biotechnology executive team
- Dr. Frank K. Bedu-Addo Ph.D.President, CEO & Director
- Mr. Stephan Toutain M.B.A., M.S.Chief Operating Officer
- Dr. Kirk V. Shepard M.D.Chief Medical Officer
- Mr. Lars Robert Boesgaard M.B.A.Principal Financial & Accounting Officer and CFO
- Dr. Gregory L. Conn Ph.D.Chief Scientific Officer
- Mr. Spencer Brown J.D.Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
- Ms. Janetta TrochimiukController